Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03740165 · ClinicalTrials.gov registry record · Phase 3
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
A Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 3
- Development phase
- 1,367
- Enrollment target
- 20
- Study locations
NCT03740165 is a Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 1,367 participants, above the 725-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (89% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT03740165, a Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,367 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of treatment with carboplatin/paclitaxel\* PLUS pembrolizumab (MK-3475) and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary peritoneal cancer. The primary study hypotheses are that the combination of pembrolizumab plus carboplatin/paclitaxel\* followed by continued pembrolizumab and maintenance olaparib is superior to carboplatin/paclitaxel alone with respect to Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in participants with programmed death-ligand 1 (PD-L1) positive tumors (Combined Positive Score \[CPS\]≥10) and in all participants, and that the combination of pembrolizumab plus carboplatin/paclitaxel followed by continued pembrolizumab is superior to carboplatin/paclitaxel alone with respect to PFS per RECIST 1.1 in participants with PD-L1 positive tumors (CPS≥10) and in all participants.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Carboplatin
- DRUG Olaparib
- DRUG Paclitaxel
- DRUG Placebo for pembrolizumab
Study Locations (20)
California
- Disney Family Cancer Center ( Site 0042) - Burbank
- Kaiser Permanente Oncology Clinical Trial -Oakland ( Site 0077) - Oakland
- Kaiser Permanente Oncology Clinical Trials-Roseville ( Site 0084) - Roseville
- Kaiser Permanente Oncology Clinical Trials-Sacramento ( Site 0083) - Sacramento
- Kaiser Permanente Oncology Clinical Trial - San Francisco ( Site 0078) - San Francisco
- Kaiser Permanente Oncology Clinical Trial - Santa Clara ( Site 0079) - Santa Clara
- Kaiser Permanente N. CA Regional Oncology Clinical Trials ( Site 0008) - Vallejo
- Kaiser Permanente Oncology Clinical Trial - Walnut Creek ( Site 0080) - Walnut Creek
Georgia
- Emory School of Medicine ( Site 0053) - Atlanta
- Northeast Georgia Medical Center ( Site 0029) - Gainesville
- Memorial Health University Medical Center ( Site 0011) - Savannah
Illinois
- Rush University Medical Center ( Site 0019) - Chicago
- University of Chicago ( Site 0049) - Chicago
- Dr. Sudarshan K. Sharma, LTD ( Site 0061) - Hinsdale
Alabama
- University of Alabama at Birmingham (UAB) ( Site 0036) - Birmingham
Arizona
- University of Arizona Cancer Center ( Site 0074) - Tucson
Connecticut
- Smilow Cancer Center at Yale-New Haven ( Site 0057) - New Haven
Florida
- Sarasota Memorial Hospital ( Site 0023) - Sarasota
Indiana
- Saint Vincent Hospital and Health Center ( Site 0012) - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,367 participants |
| Start Date | 2018-12-18 |
| Est. Completion | 2026-05-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03740165
The ClinicalTrials.gov registry entry for NCT03740165 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,367 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 725-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (89% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT03740165 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT03740165 about?
NCT03740165 is a clinical study titled "Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)". The purpose of this study is to assess the efficacy and safety of treatment with carboplatin/paclitaxel\* PLUS pembrolizumab (MK-3475) and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary peritoneal cancer. The primary study hypotheses ...
What is the current status of trial NCT03740165?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,367 participants. The study started on 2018-12-18. Estimated completion is 2026-05-29.
What conditions does trial NCT03740165 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms.
What interventions are being tested in trial NCT03740165?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Carboplatin (DRUG), Olaparib (DRUG), Paclitaxel (DRUG), Placebo for pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT03740165?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03740165 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.